147 related articles for article (PubMed ID: 25852062)
21. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
He J; Liu Y; Zhang L; Zhang H
Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
Paracchini L; Beltrame L; Grassi T; Inglesi A; Fruscio R; Landoni F; Ippolito D; Delle Marchette M; Paderno M; Adorni M; Jaconi M; Romualdi C; D'Incalci M; Siravegna G; Marchini S
Clin Cancer Res; 2021 May; 27(9):2549-2559. PubMed ID: 33323403
[TBL] [Abstract][Full Text] [Related]
23. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
24. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
[TBL] [Abstract][Full Text] [Related]
25. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
[TBL] [Abstract][Full Text] [Related]
26. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome.
Cope L; Wu RC; Shih IeM; Wang TL
Gynecol Oncol; 2013 Mar; 128(3):500-5. PubMed ID: 23200914
[TBL] [Abstract][Full Text] [Related]
27. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
28. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
29. Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c.
Fang Z; Li T; Chen W; Wu D; Qin Y; Liu M; Wu G; He L; Li H; Gu H
Exp Cell Res; 2019 Sep; 382(1):111462. PubMed ID: 31194976
[TBL] [Abstract][Full Text] [Related]
30. Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.
Jiang RT; Yemelyanova A; Xing D; Anchoori RK; Hamazaki J; Murata S; Seidman JD; Wang TL; Roden RBS
J Ovarian Res; 2017 Aug; 10(1):53. PubMed ID: 28784174
[TBL] [Abstract][Full Text] [Related]
31. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
[No Abstract] [Full Text] [Related]
32. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
[TBL] [Abstract][Full Text] [Related]
33. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract][Full Text] [Related]
34. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
35. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.
Shih IeM; Nakayama K; Wu G; Nakayama N; Zhang J; Wang TL
Mod Pathol; 2011 May; 24(5):638-45. PubMed ID: 21240255
[TBL] [Abstract][Full Text] [Related]
36. N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma.
Miranda A; Pattnaik S; Hamilton PT; Fuss MA; Kalaria S; Laumont CM; Smazynski J; Mesa M; Banville A; Jiang X; Jenkins R; Cañadas I; Nelson BH
Sci Adv; 2024 May; 10(20):eadj5428. PubMed ID: 38748789
[TBL] [Abstract][Full Text] [Related]
37. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
38. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Gong W; Liu Y; Seidl C; Dreyer T; Drecoll E; Kotzsch M; Bronger H; Dorn J; Magdolen V
PLoS One; 2019; 14(2):e0212968. PubMed ID: 30811511
[TBL] [Abstract][Full Text] [Related]
39. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
40. Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome.
Josahkian JA; Saggioro FP; Vidotto T; Ventura HT; Candido Dos Reis FJ; de Sousa CB; Tiezzi DG; de Andrade JM; Koti M; Squire JA
Int J Gynecol Cancer; 2018 Mar; 28(3):459-465. PubMed ID: 29303938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]